Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women

Mario Montanino Oliva, Giovanna Buonomo, Marco Calcagno, Vittorio Unfer, Mario Montanino Oliva, Giovanna Buonomo, Marco Calcagno, Vittorio Unfer

Abstract

Background: Myo-inositol (MI), successfully used in polycystic ovary syndrome (PCOS), was administered with α-LA to exploit its action of favouring the passage of other molecules through biological barriers, and also considering its anti-inflammatory effect.

Methods: PCOS patients, according to the Rotterdam ESHRE-ASRM criteria, with anovulation and infertility > 1 year, were included in this open and prospective study. The preliminary phase was aimed at determining a set of MI-resistant PCOS patients. This treatment involved 2 g MI, taken twice per day by oral route, for three months. The Homeostasis Model Assessment (HOMA) index and MI plasma levels were measured. In the main phase, previously selected MI-resistant patients received the same daily amount of MI plus 50 mg α-LA twice a day, for a further three months. Ovulation was assessed using ultrasound examination on days 12, 14 and 20 of the cycle. The HOMA index, lipid, hormone and MI plasma levels were detected at baseline and at the end of this phase.

Results: Thirty-seven anovulatory PCOS subjects were included in the study. Following MI treatment, 23 of the 37 women (62%) ovulated, while 14 (38%) were resistant and did not ovulate. In the latter group, MI plasma levels did not increase. These MI-resistant patients underwent treatment in the main phase of the study, receiving MI and α-LA. After this combined treatment, 12 (86%) of them ovulated. Their MI plasma levels were found to be significantly higher than at baseline; also, a hormone and lipid profile improvement was recorded.

Conclusion: The combination of MI with α-LA allowed us to obtain significant progress in the treatment of PCOS MI-resistant patients. Therefore, this new formulation was able to re-establish ovulation, greatly increasing the chances of desired pregnancy.

Trial registration: Clinical trial registration number: NCT03422289 ( ClinicalTrials.gov registry).

Keywords: Alpha-lactalbumin; Anovulation; Infertility; Myo-inositol; Polycystic ovary syndrome.

Conflict of interest statement

Ethics approval and consent to participate

This study was approved by the Ethics Committee of the Department of Woman Health and Reproductive Medicine, Santo Spirito Hospital, 00193 Rome, Italy.

Competing interests

Vittorio Unfer is employee at LoLiPharma srl. (Rome, Italy). The other authors declare no conflicts of interest.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. Revised 2003 Consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human reproduction (Oxford, England) 2004, 19(1):41–47.
    1. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774–800.
    1. Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril. 2004;81(1):114–119. doi: 10.1016/j.fertnstert.2003.05.020.
    1. Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol. 2003;46(2):325–340. doi: 10.1097/00003081-200306000-00011.
    1. Orio F, Muscogiuri G, Palomba S. Could the Mediterranean diet be effective in women with polycystic ovary syndrome? A proof of concept. Eur J Clin Nutr. 2015;69(8):974. doi: 10.1038/ejcn.2015.53.
    1. Rojas J, Chavez-Castillo M, Bermudez V. The role of metformin in metabolic disturbances during pregnancy: polycystic ovary syndrome and gestational diabetes mellitus. Int J Reprod Med. 2014;2014:797681.
    1. Zheng X, Liu Z, Zhang Y, Lin Y, Song J, Zheng L, Lin S. Relationship between Myo-inositol supplementary and gestational diabetes mellitus: a meta-analysis. Medicine. 2015;94(42):e1604. doi: 10.1097/MD.0000000000001604.
    1. Carlomagno G, Unfer V. Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci. 2011;15(8):931–936.
    1. Nestler JE, Unfer V. Reflections on inositol(s) for PCOS therapy: steps toward success. Gynecol Endocrinol. 2015;31(7):501–505. doi: 10.3109/09513590.2015.1054802.
    1. Chiu TT, Rogers MS, Law EL, Briton-Jones CM, Cheung LP, Haines CJ. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Human Reprod. 2002;17(6):1591–1596. doi: 10.1093/humrep/17.6.1591.
    1. Isabella RRE. Does ovary need D-chiro-inositol? J Ovarian Res. 2012;15(5)
    1. Ravanos K, Monastra G, Pavlidou T, Goudakou M, Prapas N. Can high levels of D-chiro-inositol in follicular fluid exert detrimental effects on blastocyst quality? Eur Rev Med Pharmacol Sci. 2017;21(23):5491–5498.
    1. Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012;28(7):509–515. doi: 10.3109/09513590.2011.650660.
    1. Kamenov Z, Kolarov G, Gateva A, Carlomagno G, Genazzani AD. Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecol Endocrinol. 2015;31(2):131–135. doi: 10.3109/09513590.2014.964640.
    1. Kamau SM, Cheison SC, Chen W, Liu X-M, Lu R-R. Alpha-Lactalbumin: its production technologies and bioactive peptides. Compr Rev Food Sci Food Saf. 2010;9(2):197–212. doi: 10.1111/j.1541-4337.2009.00100.x.
    1. Meulenbroek LA, den Hartog Jager CF, Lebens AF, Knulst AC, Bruijnzeel-Koomen CA, Garssen J, Knippels LM, van Hoffen E. Characterization of T cell epitopes in bovine alpha-lactalbumin. Int Arch Allergy Immunol. 2014;163(4):292–296. doi: 10.1159/000360733.
    1. Delavari B, Saboury AA, Atri MS, Ghasemi A, Bigdeli B, Khammari A, Maghami P, Moosavi-Movahedi AA, Haertlé T, Goliaei B: Alpha-lactalbumin: A new carrier for vitamin D3 food enrichment. Food Hydrocolloids 2015, 45(Supplement C):124–131.
    1. Wang X, Ai T, Meng XL, Zhou J, Mao XY. In vitro iron absorption of alpha-lactalbumin hydrolysate-iron and beta-lactoglobulin hydrolysate-iron complexes. J Dairy Sci. 2014;97(5):2559–2566. doi: 10.3168/jds.2013-7461.
    1. Lonnerdal B. Human milk: bioactive proteins/peptides and functional properties. Nestle Nutrition Institute workshop series. 2016;86:97–107. doi: 10.1159/000442729.
    1. Raffone E, Rizzo P, Benedetto V. Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol. 2010;26(4):275–280. doi: 10.3109/09513590903366996.
    1. Schneider S. Inositol transport proteins. FEBS Lett. 2015;589(10):1049–1058. doi: 10.1016/j.febslet.2015.03.012.
    1. Bourgeois F, Coady MJ, Lapointe JY. Determination of transport stoichiometry for two cation-coupled myo-inositol cotransporters: SMIT2 and HMIT. J Physiol. 2005;563(Pt 2):333–343. doi: 10.1113/jphysiol.2004.076679.
    1. Aouameur R, Da Cal S, Bissonnette P, Coady MJ, Lapointe JY. SMIT2 mediates all myo-inositol uptake in apical membranes of rat small intestine. Am J Physiol Gastrointest Liver Physiol. 2007;293(6):G1300–G1307. doi: 10.1152/ajpgi.00422.2007.
    1. Izumi H, Ishizuka S, Inafune A, Hira T, Ozawa K, Shimizu T, Takase M, Hara H. Alpha-Lactalbumin hydrolysate stimulates glucagon-like peptide-2 secretion and small intestinal growth in suckling rats. J Nutr. 2009;139(7):1322–1327. doi: 10.3945/jn.109.106401.
    1. Kato Y, Yu D, Schwartz MZ. Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo. J Pediatr Surg. 1999;34(1):18–20. doi: 10.1016/S0022-3468(99)90221-X.
    1. Szymlek-Gay EA, Lonnerdal B, Abrams SA, Kvistgaard AS, Domellof M, Hernell O. Alpha-Lactalbumin and casein-glycomacropeptide do not affect iron absorption from formula in healthy term infants. J Nutr. 2012;142(7):1226–1231. doi: 10.3945/jn.111.153890.
    1. Liu R, Zhang C, Shi Y, Zhang F, Li L, Wang X, Ling Y, Fu H, Dong W, Shen J, et al. Dysbiosis of gut microbiota associated with clinical parameters in polycystic ovary syndrome. Front Microbiol. 2017;8:324.
    1. Tremellen K, Pearce K. Dysbiosis of gut microbiota (DOGMA)--a novel theory for the development of polycystic ovarian syndrome. Med Hypotheses. 2012;79(1):104–112. doi: 10.1016/j.mehy.2012.04.016.
    1. Gonzalez F. Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids. 2012;77(4):300–305. doi: 10.1016/j.steroids.2011.12.003.
    1. Gonzalez F. Nutrient-induced inflammation in polycystic ovary syndrome: role in the development of metabolic aberration and ovarian dysfunction. Semin Reprod Med. 2015;33(4):276–286. doi: 10.1055/s-0035-1554918.
    1. Schippa S, Conte MP. Dysbiotic events in gut microbiota: impact on human health. Nutrients. 2014;6(12):5786–5805. doi: 10.3390/nu6125786.
    1. Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F: Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertility and sterility 2011, 95(3):1048–1058.e1041–1042.
    1. Zafari Zangeneh F, Naghizadeh MM, Masoumi M. Polycystic ovary syndrome and circulating inflammatory markers. Int J Reprod Biomed (Yazd, Iran) 2017;15(6):375–382. doi: 10.29252/ijrm.15.6.375.
    1. Maase KSJ. Use of alpha-lactalbumin as prebiotic agent. In. Edited by Wittop Koning THEPCBV. Netherlands. 2002:14.
    1. Wernimont S, Northington R, Kullen MJ, Yao M, Bettler J. Effect of an alpha-lactalbumin-enriched infant formula supplemented with oligofructose on fecal microbiota, stool characteristics, and hydration status: a randomized, double-blind, controlled trial. Clin Pediatr. 2015;54(4):359–370. doi: 10.1177/0009922814553433.
    1. Yamaguchi M, Yoshida K, Uchida M. Novel functions of bovine milk-derived alpha-lactalbumin: anti-nociceptive and anti-inflammatory activity caused by inhibiting cyclooxygenase-2 and phospholipase A2. Biol Pharm Bull. 2009;32(3):366–371. doi: 10.1248/bpb.32.366.
    1. Yamaguchi M, Takai S. Chronic administration of bovine milk-derived alpha-lactalbumin improves glucose tolerance via enhancement of adiponectin in Goto-Kakizaki rats with type 2 diabetes. Biol Pharm Bull. 2014;37(3):404–408. doi: 10.1248/bpb.b13-00762.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться